IMCC Stock Analysis: Buy, Sell, or Hold?
IMCC - IM Cannabis Corp. Common Shares
$0.23
-0.01 (-4.53%)
▼
5d:
-4.92%
30d:
-39.47%
90d:
-78.72%
BUY
HIGH Confidence
Analysis Updated: May 15, 2026 12:00 AM ET
Earnings: May 21, 2026
4d
Get Alerted When IMCC Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
2 traders called IMCC this week
100% bullish • 0 bearish
100% bullish • 0 bearish
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
✅ BUY SIGNAL: IMCC shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
✅ BUY SIGNAL: IMCC shows strong fundamentals and good volume confirmation. Solid entry point despite oversold pricing.
In-depth Analysis How we analyze
Valuation Analysis: IMCC is currently trading at $0.23, which is considered oversold relative to its 30-day fair value range of $0.25 to $0.36.
Technical Outlook: Technically, IMCC is in a strong downtrend. The price is currently testing key support at $0.23. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: IMCC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.22 (+3443.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Technical Outlook: Technically, IMCC is in a strong downtrend. The price is currently testing key support at $0.23. A bounce from this level would confirm strength, while a break below could signal further downside. Short-term momentum is weak, with the stock down 4.5% recently.
Market Sentiment: IMCC has a strong technical setup (60/100), with favorable trendlines, momentum, and price action for short-term traders. Wall Street analysts see significant upside, with an average price target of $8.22 (+3443.5%). Combining these factors, the current setup offers a favorable risk/reward ratio for buyers.
Quick Decision Summary
Current Position
OVERSOLD
Historical Trading Range
$0.25 -
$0.36
Company Quality Score
55/100
(HOLD)
Volume Confirmation
MODERATE
Confidence Score
84.2%
All Signals
- BULLISH: Price oversold vs 30-day range
- BULLISH: Strong technical setup (60/100)
- BEARISH: Downward momentum (-4.5%)
- BULLISH: Trading 3443.5% below Wall St target ($8.22)
Trading Range Analysis
30-Day Trading Range
$0.25 -
$0.36
Current vs Trading Range
OVERSOLD
Support & Resistance Levels
Support Level
$0.24
Resistance Level
$0.30
Current Trend
Strong Downtrend
Technical data as of
May 15, 2026
Fundamental Context
Forward P/E (Next Year Est.)
42.37
Wall Street Target
$8.22
(+3443.5%)
Revenue Growth (YoY)
-30.6%
Profit Margin
-27.3%
Share & Embed Analysis
Last updated: May 15, 2026 8:34 PM ET
Data refreshes hourly during market hours. Next update: 9:34 PM
Data refreshes hourly during market hours. Next update: 9:34 PM
🔥 Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is IMCC showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Drug Manufacturers - Specialty & Generic Stocks
Top-rated stocks in Drug Manufacturers - Specialty & Generic by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
NBIX
Neurocrine Biosciences I… |
STRONG BUY
25 analysts |
$191 | 63 BUY |
|
ZTS
Zoetis Inc |
STRONG BUY
19 analysts |
$136 | 57 HOLD |
|
LNTH
Lantheus Holdings Inc |
STRONG BUY
13 analysts |
$102 | 59 HOLD |
|
AQST
Aquestive Therapeutics I… |
STRONG BUY
9 analysts |
$9 | 65 BUY |
|
BCRX
BioCryst Pharmaceuticals… |
STRONG BUY
12 analysts |
$22 | 58 HOLD |
